Network Meta-Analyses in Dermatology: Can You Trust the Data? Expert Insights with Dr. Aaron Drucker

Network meta-analyses (NMAs) provide a framework for comparing dermatological treatments, yet their clinical utility hinges on methodological transparency and the presence of direct head-to-head trial data. While NMAs offer a way to rank drug efficacy, they often suffer from oversimplified ranking statistics and potential bias when funded by pharmaceutical companies. Academic-led, pre-registered analyses are generally more reliable, as they avoid the "spin" frequently found in industry-sponsored reports. Dr. Aaron Drucker, an expert in the field, highlights that direct head-to-head evidence should always take precedence over indirect comparisons when results conflict. Clinicians must critically evaluate the inclusion criteria, study populations, and specific endpoints—such as PASI 100 versus PASI 75—to determine if an NMA’s conclusions are robust enough to guide treatment decisions for conditions like atopic dermatitis, psoriasis, and hidradenitis suppurativa.